Advagene Biopharma Co., Ltd. (TPEX:6709)
23.95
+0.05 (0.21%)
Oct 8, 2026, 2:59 PM CST
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.42 billion as of October 9, 2026. It is the 31,249th most valuable company in the world and the 1,863rd biggest in Taiwan. Its market cap has decreased by 33.84% in one year.
Market Cap
1.42B
Enterprise Value
1.10B
Revenue
n/a
Global Rank
Country Rank
#1,863 Taiwan
PE Ratio
n/a
ChartMarket Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.42B, an increase of 22.73%. That is a compound annual growth rate of 2.64%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 8, 2026 | 1.42B | -14.62% |
| Dec 31, 2025 | 1.67B | 36.50% |
| Dec 31, 2024 | 1.22B | -9.95% |
| Dec 29, 2023 | 1.36B | -8.36% |
| Dec 30, 2022 | 1.48B | -38.27% |
| Dec 30, 2021 | 2.40B | 63.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 25, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Sunny Pharmtech | 1.82B |
| U-Neuron Biomedical | 1.76B |
| Synbio Tech | 1.73B |
| TaiRx | 1.69B |
| Greenyn Biotechnology | 1.57B |
| Andros Pharmaceuticals Co.,Ltd | 1.55B |
| GenMont Biotech Incorporation | 1.43B |
| Abnova (Taiwan) | 1.31B |